Entera Bio (ENTX) to Release Earnings on Friday

Entera Bio (NASDAQ:ENTX) is expected to be releasing its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect Entera Bio to post earnings of ($0.07) per share for the quarter.

Entera Bio (NASDAQ:ENTX) last released its earnings results on Friday, March 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. On average, analysts expect Entera Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Entera Bio Price Performance

Shares of NASDAQ:ENTX opened at $2.23 on Friday. The company has a 50 day moving average of $1.89 and a 200-day moving average of $2.01. Entera Bio has a one year low of $1.41 and a one year high of $2.79. The stock has a market cap of $101.29 million, a price-to-earnings ratio of -8.58 and a beta of 1.47.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Entera Bio in a report on Tuesday, March 18th.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.